ReviewNature reviews. Immunology2018
NF-κB, inflammation, immunity and cancer: coming of age.
Review in Nature reviews. Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,582 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,582 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,637 citations in OpenAlex.
- Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- DDX17 and viral infection.Virulence · 2026Review
- miR-125a-5p inhibits NF-κB by negatively regulating TRAF2 to alleviate inflammatory injury in ischemic stroke rats.IBRO neuroscience reports · 2026Article
- Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.Signal transduction and targeted therapy · 2026Review
- Acetylation-dependent nuclear translocation of EXOC4 regulates KU70 methylation to facilitate non-homologous end joining.Cell death and differentiation · 2026Article
- IL-6/IL-6R-Mediated Mechanisms in Lung Cancer: From Pathogenesis to Potential Therapeutic Targets.Immunology · 2026Review
- Truncating RELA variants drive autoinflammation and autoimmunity by impairing the negative feedback control of NF-κB.JCI insight · 2026Article
- SOX30 Facilitates Triple-Negative Breast Cancer Metastasis via TNFR2-NF-κB Signaling and Tumor Microenvironment Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pathway incompatibility between NF-κB and RAS signaling constrains oncogenicity in B-cell leukemia.The Journal of biological chemistry · 2026Article
- NF-κB/RelA signaling required for CD40-induced humoral immunity depends on specific NEMO lysine residues in mice.The EMBO journal · 2026Article
- Article
- Atriplex portulacoides L. derived phytochemicals mitigate acetic acid induced colitis in rats via orchestrating Nrf2/Keap1 signalling and LncRNAs gene expression.Inflammopharmacology · 2026Article
- Synergistic targeting of NF-κB by cinnamic and p-coumaric acids: computational and DPPH radical scavenging assessment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer.iScience · 2026Article
- Targeting the JAK/STAT signalling axis in cancer: chemopreventive potential of natural compounds with emerging focus on retinoids.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Early targeting of the YAP/TEAD-PKC-NF-κB axis alleviates post-traumatic osteoarthritis.iScience · 2026Article
- The CXCL5/CXCR2 Axis Attenuates Ferroptosis in Intrahepatic Cholangiocarcinoma Through the Positive Feedback Loop Between PTGS2 Transcriptional Activation and Neutrophil Recruitment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A TRIM15-CDX2 loop drives bile acid-induced gastric intestinal metaplasia.Molecular medicine (Cambridge, Mass.) · 2026Article
- Sustainable Valorization ofMolecules (Basel, Switzerland) · 2026Article
1,522 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fourteen years have passed since nuclear factor-κB (NF-κB) was first shown to serve as a molecular lynchpin that links persistent infections and chronic inflammation to increased cancer risk. The young field of inflammation and cancer has now come of age, and inflammation has been recognized by the broad cancer research community as a hallmark and cause of cancer. Here, we discuss how the initial discovery of a role for NF-κB in linking inflammation and cancer led to an improved understanding of tumour-elicited inflammation and its effects on anticancer immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.